286 related articles for article (PubMed ID: 34684085)
1. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.
Di Ruscio M; Lunardi G; Buonfrate D; Gobbi F; Bertoli G; Piccoli D; Conti A; Geccherle A; Variola A
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684085
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.
Mossa M; Neri B; Montesano L; Salvatori S; Marafini I; Scucchi L; Lolli E; Massoud R; Petruzziello C; Bernardini S; Calabrese E; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3787-3796. PubMed ID: 35647861
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
Berte' R; Mazza S; Stefanucci MR; Noviello D; Costa S; Ciafardini C; Mileti E; Mapelli M; Pasqualato S; Pinto S; Favale A; Vecchi M; Neurath MF; Atreya R; Fantini MC; Facciotti F; Caprioli F
J Crohns Colitis; 2021 May; 15(5):864-868. PubMed ID: 33211810
[TBL] [Abstract][Full Text] [Related]
5. High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.
Kante B; Vuyyuru SK; Gupta R; Dwivedi T; Kumar P; Mundhra S; Golla R; Virmani S; Verma M; Makharia G; Ahuja V; Kedia S
Indian J Gastroenterol; 2023 Feb; 42(1):70-78. PubMed ID: 36738383
[TBL] [Abstract][Full Text] [Related]
6. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2.
Łodyga M; Maciejewska K; Eder P; Waszak K; Stawczyk-Eder K; Michalak M; Dobrowolska A; Wiśniewska-Jarosińska M; Gąsiorowska A; Cicha M; Wierzba W; Rydzewska G
Pol Arch Intern Med; 2021 Mar; 131(3):226-232. PubMed ID: 33544564
[TBL] [Abstract][Full Text] [Related]
8. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
Wong SY; Wellens J; Helmus D; Marlow L; Brann S; Martinez Pazos V; Weinberg A; Moran HR; McGregor C; Vermeire S; Watanabe K; Kamikozuru K; Ahuja V; Vermani S; Lindsay JO; Kingston A; Dutta U; Kaur H; Silverberg MS; Milgrom R; Chien Ng S; Mak JWY; Cadwell K; Thompson C; Colombel JF; Satsangi J;
Inflamm Bowel Dis; 2023 Nov; 29(11):1693-1705. PubMed ID: 37354560
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.
Martin-Arranz MD; García-Ramírez L; Hernandez-Perez M; Montero Vega D; Martín-Arranz E; Sánchez-Azofra M; Poza Cordon J; Rueda Garcia JL; Noci Belda J; Verges Martínez-Meco T; Blanco San Miguel P; Suarez Ferrer C
Sci Rep; 2023 Apr; 13(1):7044. PubMed ID: 37120662
[TBL] [Abstract][Full Text] [Related]
10. Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease.
De Nicolò A; Cusato J; Bezzio C; Saibeni S; Vernero M; Disabato M; Caviglia GP; Ianniello A; Manca A; D'Avolio A; Ribaldone DG
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615826
[TBL] [Abstract][Full Text] [Related]
11. Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?
Malickova K; Kratka Z; Luxova S; Bortlik M; Lukas M
Scand J Gastroenterol; 2020 Aug; 55(8):917-919. PubMed ID: 32663041
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
Bezzio C; Vernero M; Costa S; Armuzzi A; Fiorino G; Ardizzone S; Roselli J; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Alimenti E; Balestrieri P; Ricci C; Cappello M; Felice C; Coppini F; Alvisi P; Di Luna I; Gerardi V; Variola A; Mazzuoli S; Lenti MV; Saibeni S;
BMC Gastroenterol; 2023 Jul; 23(1):230. PubMed ID: 37407913
[TBL] [Abstract][Full Text] [Related]
14. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
Bekic D; Belosic Halle Z
Scand J Gastroenterol; 2021 Jun; 56(6):656-660. PubMed ID: 33765405
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy.
Paduano S; Galante P; Berselli N; Ugolotti L; Modenese A; Poggi A; Malavolti M; Turchi S; Marchesi I; Vivoli R; Perlini P; Bellucci R; Gobba F; Vinceti M; Filippini T; Bargellini A
Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805539
[TBL] [Abstract][Full Text] [Related]
17. [SARS-CoV-2 Seroprevalence Among Healthcare Workers: Retrospective Analysis of the Data From A University Hospital in Turkey].
Özdemir A; Demir Çuha M; Telli Dizman G; Alp A; Metan G; Şener B
Mikrobiyol Bul; 2021 Apr; 55(2):223-232. PubMed ID: 33882653
[TBL] [Abstract][Full Text] [Related]
18. [Antibody Screening and Risk Assessment of Healthcare Professionals in the COVID-19 Pandemic].
Gümüş HH; Demiroğlu YZ; Alışkan HE; Ödemiş İ; Ceylan Ö; Poçan AG; Karagün Ö
Mikrobiyol Bul; 2021 Jul; 55(3):357-373. PubMed ID: 34416802
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
[TBL] [Abstract][Full Text] [Related]
20. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]